Aprea Therapeutics, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed July 29, 2022, reports an exchange-listing compliance matter for Aprea Therapeutics, Inc., a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol APRE. The reported event occurred July 28, 2022, with the underlying compliance period extending through July 27, 2022.
Financial and Liquidity Information
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other operating and financial metrics.
Material Changes Versus the Prior Comparable Period
On June 29, 2022, Nasdaq notified the Company that its common stock had closed below the required minimum bid price of $1.00 per share for 30 consecutive business days, resulting in noncompliance with Nasdaq Listing Rule 5450(a)(1).
Nasdaq subsequently determined that the stock maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from July 14 through July 27, 2022. The Company therefore regained compliance with the Bid Price Requirement.
Outlook, Risks, Contingencies, and Unusual Items
The principal reported contingency was the potential loss of continued listing eligibility on Nasdaq due to the bid-price deficiency. The filing states that the deficiency has been cured. It provides no financial guidance, operating outlook, financing plans, or additional risk updates.
Key Facts for Investor Verification
- Verify Nasdaq’s determination that the Company regained compliance with Listing Rule 5450(a)(1).
- Confirm the relevant compliance window: closing bid prices of at least $1.00 from July 14 through July 27, 2022.
- Review subsequent filings for any renewed bid-price deficiency, reverse stock split, or other listing-related action.
- Use the Company’s periodic reports for financial performance, liquidity, debt, cash runway, and operating risks, which are not disclosed in this Form 8-K.